Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer

International Journal of Cancer

Volumn 112, Issue 1, 2004, Pages 143-149

  Li, Qiu ^a   Wei, Yu Quan ^a   Wen, Yan Jun ^a   Zhao, Xia ^b   Tian, Ling ^a   Yang, Li ^a   Mao, Yong Qiu ^a   Kan, Bing ^a   Wu, Yang ^a   Ding, Zhen Yu ^a   Deng, Hong Xin ^a   Li, Jiong ^a   Luo, Yan ^a   Li, Hong Li ^a   He, Qiu Ming ^a   Su, Jing Mei ^a   Xiao, Fei ^a   Zou, Chun Hua ^a   Fu, Chun Hua ^a   Xie, Xing Jiang ^a   Yi, Tao ^a   Tan, Guang Hong ^a   Wang, Lian ^a   Chen, Jing ^a   Liu, Jian ^a   Gao, Zhen Nan ^a   more..

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Apoptosis; Chemotherapy; Gemcitabine; Lung cancer; Vesicular stomatitis virus

Indexed keywords

GEMCITABINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG POTENTIATION; GENE INDUCTION; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; MEDICAL ASSESSMENT; NONHUMAN; PRIORITY JOURNAL; VESICULAR STOMATITIS VIRUS; VIRAL GENE THERAPY; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARCINOMA, LEWIS LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TUMOR CELLS, CULTURED; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 4544222574     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20276     Document Type: Article

References (31)

1. Khuri FR, Herbst RS, Fossella FV. Emerging therapies in non-small-cell lung cancer. Ann Oncol 2001;12:739-44.
2. Soria J-C, Jiang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000;60:4000-4.
3. Vora SA, Daly BDT, Blaszkowsky L, McGrath JJ, Bankoff M, Supran S, Dipetrillo TA. High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma. Cancer 2000;89:1946-52.
4. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. Exploiting tumor-specific defects in the Interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-5.
5. Balachandran S. Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, ras, or myc function and involves the induction of apoptosis. J Virol 2001;75:3474-9.
6. Ebert O, Shinozaki K, Huang T-G, Savontaus MJ, Garcia-Sastre A, Woo SLC. Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003;63:3605-11.
7. Jung CP, Motwani, MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001;7:2527-36.
8. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. Evaluation of the antitumor activity of gemcitabine (2′-2′-difluoro- 2′-deoxycytidine). Cancer Res 1990;50:4417-22.
9. Braakhuis BJM, Van Dongen GAMS, Vermerken JB, Snow GB. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991;51:211-4.
10. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40.
11. Andersen H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-6.
12. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997;15:310-6.
13. Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997;15:744-9.
14. Baron F, Cueva J, Grana B, Curiel T, Leon L, Vazquez F, Candamio S, Lopez R. Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. Eur J Cancer 2001;37:1381-4.
15. Feliu J, Martin G, Lizon J, Chacon JI, Dorta J, Castro J, Rodriguez A, Sanchez Heras B, Torrego JC, Espinosa E, Gonzalez Baron M. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine: a phase II study. Ann Oncol 2001;12:1369-74.
16. Leon L, Cueva-Banuelos JF, Huidobro G, Firvida JL, Amenedo M, Lazaro M, Romero C, Estevez SV, Baron FJ, Grande C, Garcia MJ, Gonzalez A, et al. Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group. Lung Cancer 2003;40:215-20.
17. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997;15:297-303.
18. Comella P, Southern Italy Cooperative Oncology Group. Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer. Semin Oncol 2001;28:7-10.
19. Beekhuizen Ff, Beekhuizen H, van de Gevel JS, Olsson B, van Benten IJ, van Furth R. Infection of human vascular endothelial cells with staphylococcus aureus induces hyperadhesiveness for human monocytes and granulocytes. J Immunol 1997;158:774-82.
20. Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res 2002;62:3722-8.
21. Wei Y-Q, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 1994;54:4952-7.
22. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkiewicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993;53:3186-92.
23. Barry MA, Reynolds JE, Eastman A. Etoposide-induced apoptosis in human HL-60 cells is associated with intracellular acidification. Cancer Res 1993;53:2349-57.
24. Cave DR, Hendrickson FM, Huang AS. Defecive interfering virus particles modulate virulence. J Virol 1985;55:366-73.
25. Wei Y-Q, Hang Z-B, Liu K-F. In situ observation of inflammatory cell-tumor cell interaction in human seminomas (germinomas): light, electron microscopic, and immunohistochemical study. Hum Pathol 1992;23:421-8.
26. Xiao F, Wei Y-Q, Yang L, Zhao X, Tian L, Ding Z-Y, Yuan S, Lou Y-Y, Liu F, Wen Y-J, Liu J-Y, Deng H-X, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 2002;9:1207-13.
27. Nguyen JT, Wells JA. Direct activation of the apoptosis machinery as a mechanism to target cancer cells. Proc Natl Acad Sci USA 2003;100:7533-8.
28. Eastman A, Rigas JR. Modulation of apoptosis signaling pathways and cell cycle regulation. Semin Oncol 1999;26:7-16.
29. Kopecky SA, Lyles DS. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 2003;77:5524-8.
30. Hobbs JA, Hommel-Berrey G, Brahmi Z. Requirement of caspase-3 for efficient apoptosis induction and caspase-7 activation but not viral replication or cell rounding in cells infected with vesicular stomatitis virus. Hum Immunol 2003;64:82-92.
31. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, Hertel LW, Yu S, Pon RT, Gmeiner WH, Pommier Y. Gemcitabine (2′,2′-difluoro- 2′-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 2002;8:2499-504.